A real-world study found that mailed self-collection HPV tests significantly increased cervical cancer screening participation among never- and under-screened US women. Women who received the self-collection kits were more than twice as likely to participate in screening compared to those who received only a telephone reminder.
A Phase I/II study has demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN) treated with pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123. The overall response rate was 85%, including a complete response rate of 70%.
A new therapy combining pembrolizumab with targeted therapies before surgery improved tumor removal and overall survival for patients with BRAF-mutated anaplastic thyroid cancer. The treatment increased response rates and showed better outcomes compared to standard therapy.
A Phase III trial led by MD Anderson Cancer Center demonstrates a triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improves progression-free survival and overall survival in BRAF V600E-mutated metastatic colorectal cancer. The regimen offers a clear survival advantage over standard chemotherapy alone.
A new study from the University of Texas MD Anderson Cancer Center reveals that nearly 60% of U.S. adults are unaware or uncertain of the link between alcohol and cancer, despite established connections. The findings highlight the need for improved public awareness and urge clinicians to speak with their patients directly.
Researchers identified a new biomarker, TTF-1, that predicts survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib. Patients with low TTF-1 levels responded poorly to sotorasib, while those with high TTF-1 levels showed improved outcomes.
Christopher Flowers is being recognized for his commitment to mentoring young oncology professionals. He has advanced the development of multiple new treatments and helped characterize disparities in outcomes among patients with lymphoma.
Researchers from MD Anderson Cancer Center present notable studies on immunotherapy and CAR T cell therapy for various cancer types. These findings show promising results for patients with aggressive and rare cancers.
Researchers at MD Anderson Cancer Center have made significant discoveries in three key areas of cancer care. In a study on sickle cell disease, the team found that the disorder can suppress immunity by altering DNA structure in CD8+ T cells, leading to potential strategies for improving immunotherapy responses. Meanwhile, a biomarker-...
The University of Texas MD Anderson Cancer Center has been awarded $21.4 million by CPRIT to support cancer research efforts and faculty recruitment. The institution is grateful for the continued funding, which will help advance future potential breakthroughs in cancer treatment.
The $150 million gift from Kinder Foundation will create a joint venture between UT MD Anderson Cancer Center and Texas Children's Hospital, aiming to end childhood cancer. The center will be the nation's largest and most comprehensive pediatric cancer center focused exclusively on children.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
AIC100 demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, including anaplastic thyroid cancer (ATC) and relapsed/refractory poorly differentiated thyroid cancer (PTDC). The therapy showed significant tumor shrinkage and disease control in 56% of patients.
A Phase Ia/Ib trial found that zongertinib demonstrated clinical benefits for patients with advanced HER2-mutant non-small cell lung cancer, particularly those with specific HER2 mutations. The treatment showed a 71% objective response rate and manageable side effects.
A clinical trial found that LUT014, a topical BRAF inhibitor, significantly reduced the severity of acne-like skin rashes caused by targeted therapy for colorectal cancer. Patients who received LUT014 had improved quality of life and were able to continue receiving their cancer treatment with reduced side effects.
A Phase II trial found durable antitumor activity in patients with BRCA1/2 mutations treated with olaparib and pembrolizumab, with 8.3% complete response rate
The treatment demonstrated early signals of efficacy, with 65.7% of patients experiencing lasting stable disease, and was generally well-tolerated, with most adverse events being mild and manageable.
Researchers at MD Anderson Cancer Center present promising results from clinical trials in three minisymposia abstracts. The studies explore personalized vaccine combination therapy for colorectal cancer, radiotherapy to avoid toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancrea...
Five MD Anderson researchers will receive the AACR Scientific Achievement Awards for their significant contributions to translational research and oncology leadership. The honorees include Robert Bast, Ronald DePinho, Christopher Flowers, Han Liang, and another researcher not specified in this article.
John N. Weinstein, MD, PhD, chair of Bioinformatics and Computational Biology at MD Anderson Cancer Center, has been elected Fellow of the American Association for Cancer Research (AACR) Academy. He made significant contributions to advancing our knowledge of molecular profiles of cancer through multi-omic studies and data analysis.
Researchers at MD Anderson Cancer Center have discovered that adding copper-loaded agents to radiotherapy can overcome radioresistance in preclinical models of thoracic cancer. A novel blood-based biomarker, OSMR, has also been identified in patients with acute myeloid leukemia (AML), which shows prognostic potential and can help ident...
A Phase I trial demonstrates AFM13-NK cells are safe and highly effective in heavily pretreated patients with refractory CD30-positive lymphomas, achieving an overall response rate of 92.9% and complete response of 66.7%. The treatment was well-tolerated, with no cases of cytokine release syndrome or graft-versus-host disease.
The new facility will offer a range of services including ambulatory surgery, expanded diagnostic imaging, and outpatient procedural services. It is designed to provide comprehensive cancer care for adult patients with low-to-medium acuity needs.
Researchers at MD Anderson Cancer Center made several key discoveries, including the spatial organization of cancer-associated fibroblasts across various cancers and a study on treatment resistance in SMARCA4-mutant lung cancer. These findings highlight the importance of investigating cell populations in their spatial context to better...
Lauren Byers, a lung cancer clinician and prevention expert, was elected for her contributions to small cell lung cancer research. Paul Scheet, chair of Epidemiology, was recognized for his extensive work in genetic epidemiology and cancer genomics.
Jeffrey E. Lee, M.D. has been appointed Chief Medical Executive at MD Anderson, succeeding Dr. Peter WT Pisters. With over 34 years of tenure, Lee will lead the institution's efforts in research, patient care, prevention, and education. He brings a strong track record of leadership and clinical expertise to the role.
Researchers at MD Anderson have made significant breakthroughs in understanding pancreatic cancer's evolutionary process and developing new treatment strategies. They also discovered that surgical resection can enhance antitumor response in patients receiving immune checkpoint therapy for advanced kidney cancer.
The F. W. Bert and Mae Dean Wheeler Nurse Leadership Academy at MD Anderson aims to cultivate oncology nurse leaders through coaching, mentoring, and continuous learning opportunities. The academy will focus on empowering nurses to reach their personal and professional goals, driving industry change and improving healthcare systems.
Researchers at MD Anderson Cancer Center have identified biomarkers for predicting treatment response in metastatic breast cancer and found a potential target for tumor progression in pancreatic cancer. Additionally, they discovered that abnormal chromosome changes predict survival in patients with secondary acute myeloid leukemia.
Researchers at MD Anderson Cancer Center have developed a novel antibody-toxin conjugate that stimulates the immune system to recognize and attack cancer cells. The new approach combines the benefits of ADCs with immunotherapies, allowing the body's natural immune response to limit side effects and prevent tumor recurrence.
The joint venture aims to build the world's preeminent pediatric cancer center, increasing access to care and clinical trials. Collaborative operations will launch in early 2026, featuring a focus on new facilities with latest medical technology.
The University of Texas MD Anderson Cancer Center received nearly $23 million in CPRIT funding to advance cancer research, translational science, and clinical trials. The funding will support the recruitment of a first-time tenure-track faculty member and enhance the understanding of cancer biology.
Researchers found a biomarker, RNA Polymerase II (RNAPII), associated with tumor aggressiveness and recurrence in meningioma and breast cancers. The study developed a novel profiling technology, Cleavage Under Targeted Accessible Chromatin (CUTAC), to measure gene transcription activity from DNA, which predicted cancer outcomes.
Researchers at MD Anderson Cancer Center have made significant advancements in treating oligometastatic prostate cancer, advanced urothelial cancer, and triple-negative breast cancer. Personalized risk-based screening is also being explored as a tool to reduce cancer deaths.
Patients with BRAF V600E mutations showed a 60.9% overall response rate to a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy, compared to 40% with standard-of-care treatment. This triple-combination therapy offers an effective new first-line treatment option for patients with this mutation.
MD Anderson researchers have made significant breakthroughs in treating relapsed or refractory B-cell lymphoma with a novel allogeneic NK cell therapy. Additionally, targeted therapies have shown responses in HER2-mutant metastatic breast cancer, while a triplet combination of sitravatinib and immune checkpoint inhibitors has demonstra...
Be Well Beaumont aims to promote wellness and lower cancer risk among community members through cancer prevention education and tools. The initiative will focus on healthy eating, active living, sun safety, tobacco-free living, and preventive care.
Integrated care, combining medication and comprehensive counseling with tobacco treatment specialists, significantly improves quitting chances among smokers undergoing lung cancer screening. This randomized clinical trial found nearly two-fold improvement in quitting rates compared to other cessation methods.
Researchers discovered a key role for neutrophils in cancer cell colonization of abdominal fat through the release of DNA webs called NETs. Additionally, a new biomarker study found that dose-dense chemotherapy improved disease-free survival by 20% and overall survival by 15% for women with early-stage ER-positive breast cancer.
The alliance aims to generate evidence supporting national guideline inclusion and healthcare provider adoption of Myriad's Precise MRD test. The studies will explore the test's utility in breast, gastrointestinal, genitourinary and gynecological cancers.
Research from the University of Texas M. D. Anderson Cancer Center suggests that individuals with pre-existing cardiovascular disease are more likely to have advanced or metastatic breast cancer. The study found a 10% increased risk of CVD in patients with late-stage breast cancer compared to those with early-stage cancer.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
Lauren Averett Byers, a professor at MD Anderson Cancer Center, has received the 2025 Edith and Peter O'Donnell Award in Medicine from Texas Academy of Medicine, Engineering, Science and Technology (TAMEST) for her fundamental discoveries in small cell lung cancer. Her work has led to personalized treatments and improved patient outcomes.
The collaboration aims to evaluate the potential of AMB-066 as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease. MD Anderson researchers have identified a potential opportunity for AMB-066 to effectively treat MRD-positive CRC, based on robust preclinical data.
Researchers observed a 100% response rate on Phase Ib trial for patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis. Early intervention with ELA026 may provide meaningful clinical benefits for patients with few options.
The study presents strong overall responses with a triplet regimen including a novel menin inhibitor, achieving an 82% overall response rate in relapsed or refractory acute myeloid leukemia patients. The combination also demonstrated manageable side effects and significant clinical benefits, providing patients with improved treatment o...
Researchers at MD Anderson Cancer Center presented findings on novel treatments for MDS, including luspatercept, which significantly reduced the need for blood transfusions in lower-risk patients. Additionally, a triplet therapy regimen improved survival in older adults with FLT3-mutated AML.
The Phase Ib/II FELIX trial demonstrated a 76.6% response rate and 55.3% complete remission rate in 127 evaluable patients treated with obe-cel CAR T cell therapy. The median event-free survival was 11.9 months, and the overall survival was 15.6 months.
MD Anderson researchers have made significant advancements in treating chronic pain, myelodysplastic syndrome, and rare cancers. A novel treatment for chronic pain has been developed with reduced side effects, while targeted therapies like canakinumab show promise for personalized approaches.
The University of Texas MD Anderson Cancer Center has been awarded nearly $8 million in CPRIT funding to support lung and colorectal cancer screening programs, as well as faculty recruitment. The funding will enable the expansion of these programs to address high cancer incidence rates across Texas.